B. Riley Comments on LifeMD’s Q1 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Equities researchers at B. Riley issued their Q1 2025 EPS estimates for shares of LifeMD in a note issued to investors on Tuesday, March 11th. B. Riley analyst A. Schock forecasts that the company will post earnings of ($0.07) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. B. Riley also issued estimates for LifeMD’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.10) EPS.

A number of other brokerages also recently issued reports on LFMD. KeyCorp dropped their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Mizuho began coverage on shares of LifeMD in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research report on Tuesday. Lake Street Capital began coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright boosted their target price on shares of LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, LifeMD currently has a consensus rating of “Buy” and an average price target of $11.43.

LifeMD Stock Performance

Shares of NASDAQ LFMD opened at $5.94 on Friday. The company has a market capitalization of $257.27 million, a P/E ratio of -9.28 and a beta of 1.50. LifeMD has a 52-week low of $3.99 and a 52-week high of $12.88. The company’s 50 day moving average price is $5.68 and its 200-day moving average price is $5.38.

LifeMD (NASDAQ:LFMD) last posted its earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $64.26 million for the quarter, compared to the consensus estimate of $57.43 million.

Insider Activity at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. This represents a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 15.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeMD

Several institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in LifeMD by 20.0% during the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after purchasing an additional 192,861 shares during the last quarter. Royce & Associates LP lifted its holdings in LifeMD by 23.9% during the fourth quarter. Royce & Associates LP now owns 1,115,991 shares of the company’s stock valued at $5,524,000 after purchasing an additional 214,950 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in LifeMD by 21.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company’s stock valued at $4,610,000 after purchasing an additional 165,378 shares during the last quarter. Millennium Management LLC lifted its holdings in LifeMD by 17.1% during the fourth quarter. Millennium Management LLC now owns 885,987 shares of the company’s stock valued at $4,386,000 after purchasing an additional 129,327 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in LifeMD by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock valued at $4,071,000 after purchasing an additional 2,984 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.